MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients

Wen, Jianqiong; Xu, Houyi; Liu, Renying; Chen, Qiaoxiu; Dai, Yinhua; Xu, Yong

doi:10.14715/cmb/2020.66.3.4

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the prognosis of TPF is worth studying. microRNA-92b is a marker for predicting the response to TPF induction chemotherapy and evaluating the prognosis of patients with advanced OSCC [30]. In addition, in our previous studies, the expression of stromal cell derived factor-1 and nerve growth factor (NGF) was up-regulated in the tumor stage of TNM, while NGF protected salivary glands from radiotherapy damage [31].…”

Section: Discussionmentioning

confidence: 95%

Neoadjuvant Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Single Center Study

weili²,

Tian³

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective:Aimed to evaluate the effect and response from the adjuvant chemotherapy for locally advanced oral squamous cell carcinoma. Methods: Retrospectively collected 46 patients with local late oral squamous cell carcinoma admitted from 2017 to 2021. The patients were treated with TPF induction chemotherapy. All patients completed at least 2 cycle of TPF (PF) regimen (75 mg / m2 of docetaxel on day 1 + 75 mg / M2 of cisplatin on day 1 + 750 mg / m2 of 5-fluorouracil on days 1 ~ 5, one cycle every 21 days), The primary end-points were overall response rate, safety of therapy and overall survival were evaluated. Results: After two cycles of TPF treatment, patients continued receiving surgery followed by radiotherapy or chemotherapy, include 5 patients were received PF. The complete remission rate was 6.25% (2/32), and the objective remission rate was 71.88% (23/32). Most of the adverse factors of chemotherapy response are alleviated. The median follow-up time was 26 months, and the median OS was 25.51 ± 3.81 months. Conclusion: Neoadjuvant chemotherapy, such as TPF or PF, plays an important role in the comprehensive treatment of advanced OSCC and postoperative assessments of white blood cell can provide high-quality prognostic information.

show abstract

Section: Discussionmentioning

confidence: 95%

Neoadjuvant Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Single Center Study

weili²,

Tian³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Although some studies have shown that miR-92b may be related to the proliferation and chemotherapy response of oral squamous cell carcinoma (OSCC) [ 22 , 23 ], its specific biological role and molecular mechanism in the invasion and migration of HNSCC are still unclear. In this regard, we hypothesized that miR-92b plays an important role in the development of HNSCC, and studied whether transcription factor SP1 promotes the invasion and migration of head and neck squamous cell carcinoma cells through the interaction with miR-92b, supporting a novel feed-forward loop with a significantly important role in the progression of HNSCC.…”

Section: Introductionmentioning

confidence: 99%

Specificity protein 1/microRNA-92b forms a feedback loop promoting the migration and invasion of head and neck squamous cell carcinoma

Pang

Fang

et al. 2021

Bioengineered

View full text Add to dashboard Cite

In this study we report a novel specificity protein 1 (SP1)/microRNA-92b (miR-92b) feedback loop regulating the migration and invasion of head and neck squamous cell carcinoma (HNSCC). Microarray and real-time Polymerase Chain Reaction (PCR) were used to detect gene expression in HNSCC tissues and cell lines. Transwell migration, invasion, wound healing and cell counting kit – 8 (CCK-8) cell assays were used to compare cell migration, invasion and proliferation abilities. Chromatin Immunoprecipitation (ChIP) assays were used to detect SP1 binding to the miR-92b promoter. Western blot was used to detect protein levels. An in vivo tumorigenesis experiment was used to evaluate the effect of SP1 knockdown on tumor growth and protein levels were evaluated by immunohistochemistry. We found that the miR-92b expression level was elevated in HNSCC primary focus tissue compared with adjacent normal tissue, and a higher level of miR-92b was related to a higher clinical stage and worse prognosis of HNSCC patients. MiR-92b and SP1 mutually promoted each expression and cooperatively facilitated the migration, invasion and proliferation of HNSCC cells. A decreased level of SP1/miR-92b resulted in a restraint of in vivo tumor growth. In conclusion, our results suggest that the SP1/miR-92b feedback loop generally promotes HNSCC invasion and metastasis, thus presenting a possible therapeutic target in the treatment of HNSCC patients.

show abstract

Frontiers and hotspots in induction chemotherapy of oral squamous cell carcinoma: a bibliometric and visualized study from 2000 to 2022 by Bioinformatics and Cancer Database Analysis

Xu,

Wu,

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives: Oral squamous cell carcinoma (OSCC) is a prevalent malignant tumor worldwide, posing a significant threat to patient survival. Induction chemotherapy (IC) is an established therapeutic approach for advanced, unresectable OSCC, proven effective in controlling tumor progression and preventing distant metastasis. Despite its clinical significance, there is a lack of bibliometric studies in this research domain. This article aims to address this gap by conducting a comprehensive bibliometric analysis, which will shed light on the key areas of focus and provide insights into the research landscape of OSCC induction chemotherapy. Methods: The relevant articles were identified using the Web of Science Core Collection (WoSCC). To examine the co-occurrence relationships across countries/regions, institutes, authors (cited authors), journals (cited journals), references, and keywords in this research field, bibliometric analysis was conducted with the assistance of two software tools, VOSviewer and CiteSpace. This approach enables a comprehensive exploration of the frontiers and hotspots within the field. Results: A comprehensive collection of 227 publications was assembled between 2000 and 2022. Overall, both the number of publications and citations display a steady annual increase, with the peak observed in 2021 and 2022. China and the United States jointly occupy the first rank in terms of total publications (n = 46), with Japan following closely behind (n = 32). Among the academic institutions, Shanghai Jiao Tong University has made the most substantial contribution, with 26 publications. In the realm of authors, Zhong Laiping secures the top position in the list of the top 10 authors (n = 13), whereas Posner MR and Vermorken JB are equally distinguished as the most co-cited authors (n = 104). The research field's most prolific journal is Oral Oncology, which boasts the highest number of publications (n = 24), while the Journal of Clinical Oncology claims the greatest number of co-citations. Conducting a co-occurrence and cluster analysis on the references cited, it was discovered that the recent research focus has shifted from radiochemotherapy and oral cancer to paclitaxel. Keyword analysis unveils that current research on induction chemotherapy for OSCC underscores the significance of chemotherapeutic drugs such as cisplatin, docetaxel, and fluorouracil. Conclusion: Despite the relatively modest number of publications, research on induction chemotherapy for OSCC is steadily growing. Currently, the primary focus of investigation revolves around drug selection for this therapeutic approach. This article provides an overview of the prevailing trends in this field and identifies potential directions and hotspots for future research.

show abstract

MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients

Cited by 4 publications

References 36 publications

Neoadjuvant Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Single Center Study

Neoadjuvant Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Single Center Study

Specificity protein 1/microRNA-92b forms a feedback loop promoting the migration and invasion of head and neck squamous cell carcinoma

Frontiers and hotspots in induction chemotherapy of oral squamous cell carcinoma: a bibliometric and visualized study from 2000 to 2022 by Bioinformatics and Cancer Database Analysis

Contact Info

Product

Resources

About